Search clinical trials for: CD4 CAR CCR5 ZFN T-cells

Total 885 results

University of Pennsylvania

Active, not recruiting

CD4 CAR+ ZFN-modified T Cells in HIV Therapy

Hiv

United States
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies

Refractory T-Cell Lymphoma | T Cell Lymphoma in Relapse

China
Beijing GoBroad Hospital

Not yet recruiting

CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic Leukemia | T-Cell Acute Lymphocytic Leukemia
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Clinical Study of Targeting CD7 CAR-T Cells in the Treatment of Autoimmune Diseases

Autoimmune Diseases | Crohn Disease | Ulcerative Colitis | Dermatomyositis | Still Disease

China
Assistance Publique - Hôpitaux de Paris

Completed

Injection of CD4 and CD8 + T Cells Anti-Cytomegalovirus (CMV) or Anti-adenovirus (CTLantiCMV)

Cytomegalovirus Infections | Adenovirus Infections

France
Shenzhen University General Hospital

Recruiting

CD7 CAR-T Cells in T-cell Lymphoma/Leukemia

T Lymphoblastic Leukemia/Lymphoma

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances

T-cell Acute Lymphoblastic Leukemia | T-cell Non-Hodgkin Lymphoma | T-cell Acute Lymphoblastic Lymphoma

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases

Neoplasms | Hematologic Diseases

China
Beijing GoBroad Hospital

Recruiting

Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Acute Lymphoblastic Leukemia/Lymphoma

Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Leukemia

China
Shanghai General Hospital, Shanghai Jiao Tong University...

Recruiting

Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies

Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Peripheral T Cell Lymphoma | T-cell Acute Lymphoblastic Leukemia | T Lymphoblastic Leukemia/Lymphoma

China
The First Affiliated Hospital of Soochow University
Affiliated Hospital of Jiangnan University; The Affiliated Nanjing Drum Tower... and other collaborators

Recruiting

CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma

Refractory and Relapsed T Cell Lymphoma

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies (CD5CAR-T)

T-cell Acute Lymphoblastic Leukemia | T-cell Non-Hodgkin Lymphoma

China
Bioceltech Therapeutics, Ltd.

Recruiting

Chimeric Antigen Receptor T-Cell (CAR-T) Cells in Patients With R/R T-LBL

T Cell Lymphoblastic Lymphoma

China
University of Pennsylvania

Completed

Autologous CD4 T-Cells in HIV (C34-CXCR4)

Hiv

United States
Nantes University Hospital

Completed

Study of the Frequency and of the Regulatory Function of Positive T Lymphocytes Dual CD4CD8aa (DP8a) Specific to a Bacteria of the Intestinal Microbiota (Faecalibacterium Prausnitzii) in Atopic Dermatitis, Asthma and Allergic Rhinitis (Prévall-DP)

Allergic Rhinitis | Atopic Dermatitis | Allergic Asthma

France
Shenzhen Geno-Immune Medical Institute

Recruiting

Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

Acute Myeloid Leukemia | T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | NK Cell Lymphoma

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Juno Therapeutics, Inc.

Completed

Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Daniel Landi

Terminated

EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma (ExCeL)

Glioblastoma | Gliosarcoma

United States
Shenzhen Geno-Immune Medical Institute
The Second Affiliated Hospital of Hainan Medical University; Beijing Jingdu...

Recruiting

Universal 4SCAR7U Targeting CD7-positive Malignancies

Acute Myeloid Leukemia | T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | NK Cell Lymphoma

China
VIRxSYS Corporation

Active, not recruiting

A Rollover Study for Subjects Who Completed Participation in the VRX496-USA-05-002 Trial (Rollover)

HIV Infections

United States
The First Affiliated Hospital of Soochow University
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia

Acute Myeloid Leukemia | Mixed Phenotype Acute Leukemia | T Lymphoblastic Leukemia/Lymphoma

China
Masonic Cancer Center, University of Minnesota

Terminated

Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease

United States
University of Colorado, Denver

Recruiting

UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1

Acute Lymphoblastic Leukemia | Acute Lymphoid Leukemia

United States
University of Pennsylvania
M.D. Anderson Cancer Center

Completed

CD3/CD28 Bead Activated T-Cells Following Chemo-Immunotherapy in Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Essen Biotech

Not yet recruiting

Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells (BAH246)

T Cell Lymphoma | T Cell Prolymphocytic Leukemia | T-cell Acute Lymphoblastic Leukemia | T Cell Leukemia | T-Cell Lymphoma of CNS | T Cell Childhood ALL

China
Southwest Hospital, China

Unknown

the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)

Lymphoma, Large B-Cell, Diffuse

China
Everett Meyer
National Cancer Institute (NCI)

Withdrawn

Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant

Graft Versus Host Disease

United States
Cancer Institute and Hospital, Chinese Academy...
UTC Therapeutics Inc.

Not yet recruiting

MSLN-targeted CAR-T Cells in Solid Tumors.

Mesothelin-positive Advanced Malignant Solid Tumors
The First Affiliated Hospital of Soochow University

Recruiting

Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

China
920th Hospital of Joint Logistics Support Force...

Withdrawn

A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL

T-lymphoblastic Lymphoma | T-cell Acute Lymphoblastic Leukemia

China
Wuhan Sian Medical Technology Co., Ltd
Wuhan Union Hospital, China; Xiangyang Central Hospital; Jingzhou Central Hospital and other collaborators

Unknown

CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies

B Cell Lymphoma | Acute Lymphoblastic Leukemia

China
Seattle Children's Hospital

Active, not recruiting

Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia

CD 19+ Acute Leukemia

United States
BioSyngen Pte Ltd

Completed

A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma

EBV-positive Nasopharyngeal Carcinoma

China
Affiliated Hospital of Jiangnan University
West China Hospital; Hunan Cancer Hospital; Shenzhen Second People's Hospital; Zhejiang... and other collaborators

Recruiting

IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites

Pleural Effusion, Malignant

China
Medical College of Wisconsin
Children's Hospital and Health System Foundation, Wisconsin

Recruiting

CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL (CAR-20/19-T)

Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia Recurrent | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved Remission

United States
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma

Non-hodgkin Lymphoma,B Cell

China
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies

Infectious Diseases | Hematological Malignancies

China
He Huang
Gracell Biotechnology Ltd.

Not yet recruiting

Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma

Relapsed and Refractory | Lymphoid Hematological Malignancies

China
Zhejiang University

Recruiting

A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia

China
Xuanwu Hospital, Beijing
Baoding Children's Hospital

Recruiting

CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia

T-cell Acute Lymphoblastic Leukemia

China
Medical College of Wisconsin
Children's Hospital and Health System Foundation, Wisconsin

Completed

Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell

Lymphoma, B-Cell | Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases

Acute Myeloid Leukemia | Multiple Myeloma | Non-hodgkin's Lymphoma

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Guangzhou Bio-gene Technology Co., Ltd

Active, not recruiting

A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma

T-Cell Acute Lymphocytic Leukemia

China
Beijing GoBroad Hospital

Recruiting

Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients

Acute Lymphoblastic Leukemia, in Relapse | B-cell Acute Lymphoblastic Leukemia | Refractory Acute Lymphoid Leukemia

China
920th Hospital of Joint Logistics Support Force...

Recruiting

Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia

Acute Myeloid Leukemia

China
Sorrento Therapeutics, Inc.

Completed

Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients

Relapsed or Refractory Multiple Myeloma

United States
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma

Multiple Myeloma | New Diagnosis Tumor

China
Peking University People's Hospital

Not yet recruiting

CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

T-cell Non-Hodgkin's Lymphoma

Search clinical trials for: CD4 CAR CCR5 ZFN T-cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations